Stem Cell Therapy for Outer Retinal Degenerations
Primary Purpose
Age Related Macular Degeneration, Stargardt's Disease, Exudative Age-related Macular Degeneration
Status
Completed
Phase
Phase 1
Locations
Brazil
Study Type
Interventional
Intervention
injection of hESC-RPE in suspension
injection hESC-RPE seeded in a substrate
Sponsored by
About this trial
This is an interventional treatment trial for Age Related Macular Degeneration
Eligibility Criteria
Inclusion Criteria:
- Patients with AMD ( Dry , Wet after failure of treatment, disciform scars)
- Patients with Stargardt's Disease BCVA on the selected eye: worse than 20/200
Exclusion Criteria:
- Other ophthalmological diseases( Glaucoma, Diabetic Retinopathy, Previous retinal surgery, uveitis)
- Systemic diseases with contraindication for surgical procedures with local anaesthesia
Sites / Locations
- Federal University of Sao Paulo
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
injection of hESC-RPE in suspension
injection hESC-RPE seeded in a substrate
Arm Description
6 patients will receive cell suspension injections on the sub retinal space prior to the surgeries, to access safety
15 patients will receive a sub-retinal implantation of a polymeric scaffold seeded hesc- RPE in monolayer
Outcomes
Primary Outcome Measures
Incidence of Treatment-Emergent Adverse Events of sub retinal implantation of stem cell derived retinal pigmented epithelium in the sub retinal space.
Incidence of surgical related side effects: Retinal detachment, Ocular inflammation, Increase in intraocular pressure, Infection( endophthalmitis), Loss of vision due to surgical, related complications
Secondary Outcome Measures
Incidence of side effects related to the treatment itself( injection and implantation of sub retinal stem cell related RPE)
Inflammation/rejection Cell migration/differentiation Tumor formation Proliferative vitreoretinopathy/Retinal detachment Implant migration
Full Information
NCT ID
NCT02903576
First Posted
March 7, 2016
Last Updated
July 20, 2020
Sponsor
Federal University of São Paulo
1. Study Identification
Unique Protocol Identification Number
NCT02903576
Brief Title
Stem Cell Therapy for Outer Retinal Degenerations
Official Title
Stem Cell Derived Retinal Pigmented Epithelium Implantation in Patients With Outer Retinal Degenerations: Phase I/II Clinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
August 2017
Overall Recruitment Status
Completed
Study Start Date
August 2015 (undefined)
Primary Completion Date
January 2019 (Actual)
Study Completion Date
June 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Federal University of São Paulo
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study is a Phase I/II , open label,non randomized, prospective study to determine the safety of human embryonic stem cell derived Retinal pigmented epithelium (hESC RPE) sub retinal injections versus hESC RPE seeded on a polymeric substrate implanted in the sub retinal space,
Detailed Description
To determine whether the surgical implantation of a human embryonic stem cell-derived retinal pigmented epithelium (hESC-RPE) monolayer seeded onto a polymeric versus hESC-RPE injections into the sub retinal space is a safe procedure.
6 Patients will receive hESC-RPE cell injections (100000 cells) in the sub retinal space (2 Dry Age-related macular degeneration (AMD), 2 Wet AMD with disciform scar and 2 with Stargardt's disease).
Also 5 patients Dry AMD, 5 patients with Wet AMD with disciform scar and 5 patients with Stargardt's disease with receive a subretinal implantation of the hESC-RPE seeded in a monolayer in a polymeric substrate.
Patients will be enrolled sequentially, and after the procedure the patients will be followed for 1 year.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Age Related Macular Degeneration, Stargardt's Disease, Exudative Age-related Macular Degeneration
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
15 (Actual)
8. Arms, Groups, and Interventions
Arm Title
injection of hESC-RPE in suspension
Arm Type
Active Comparator
Arm Description
6 patients will receive cell suspension injections on the sub retinal space prior to the surgeries, to access safety
Arm Title
injection hESC-RPE seeded in a substrate
Arm Type
Active Comparator
Arm Description
15 patients will receive a sub-retinal implantation of a polymeric scaffold seeded hesc- RPE in monolayer
Intervention Type
Procedure
Intervention Name(s)
injection of hESC-RPE in suspension
Other Intervention Name(s)
Human Embryonic Stem Cell - Retinal Pigmented Epithelium
Intervention Description
The first six patients will receive a sub retinal injection of hESC-RPE in solution after a complete pars plana vitrectomy to access safety of the cell implant alone.
Intervention Type
Procedure
Intervention Name(s)
injection hESC-RPE seeded in a substrate
Other Intervention Name(s)
Human Embryonic Stem Cell seeded in a polymeric substrate
Intervention Description
Fifteen patients will receive a sub-retinal implantation of embryonic stem cell derived retinal pigmented epithelium seeded in a polymeric substrate to access safety of substrate seeded with RPE
Primary Outcome Measure Information:
Title
Incidence of Treatment-Emergent Adverse Events of sub retinal implantation of stem cell derived retinal pigmented epithelium in the sub retinal space.
Description
Incidence of surgical related side effects: Retinal detachment, Ocular inflammation, Increase in intraocular pressure, Infection( endophthalmitis), Loss of vision due to surgical, related complications
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Incidence of side effects related to the treatment itself( injection and implantation of sub retinal stem cell related RPE)
Description
Inflammation/rejection Cell migration/differentiation Tumor formation Proliferative vitreoretinopathy/Retinal detachment Implant migration
Time Frame
1 year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with AMD ( Dry , Wet after failure of treatment, disciform scars)
Patients with Stargardt's Disease BCVA on the selected eye: worse than 20/200
Exclusion Criteria:
Other ophthalmological diseases( Glaucoma, Diabetic Retinopathy, Previous retinal surgery, uveitis)
Systemic diseases with contraindication for surgical procedures with local anaesthesia
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rubens Belfort, MD
Organizational Affiliation
Federal University of São Paulo UNIFESP
Official's Role
Study Chair
Facility Information:
Facility Name
Federal University of Sao Paulo
City
Sao Paulo
ZIP/Postal Code
04023-062
Country
Brazil
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
scientific publication in a peer review journal
Learn more about this trial
Stem Cell Therapy for Outer Retinal Degenerations
We'll reach out to this number within 24 hrs